novel treatments

OBL Corner

Read more about OBL Corner
123 views

Conference Coverage

ASCO Annual Meeting 2020

05/27/2020

The ASCO 2020 Virtual Scientific Program (May 29-31) provided the opportunity to connect with oncology professionals around the world to explore and discuss cutting-edge research, therapies, and state-of-the-art...

The...

05/27/2020

Journal of Clinical Pathways

Research in Review

Novel Prostate Cancer Biomarkers May Improve Targeted Therapy

08/15/2017

JCP Editors

Recent research has uncovered a new cause of treatment resistance in prostate cancer, which may improve targeted therapy efforts. Mutations within the SPOP gene are the most frequently documented genetic changes in...

Recent...

08/15/2017

Journal of Clinical Pathways

Research in Review

Double Dosage of ALK Inhibitor Improves Outcomes in NSCLC

08/09/2017

JCP Editors

Increasing the standard dose of an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of non-small cell lung cancer (NSCLC) improves objective response rates (ORR) by 9% with limited additional toxicity,...

...

08/09/2017

Journal of Clinical Pathways

Research in Review

Triplet Combination Shows Durable Responses in Advanced Multiple Myeloma

07/17/2017

JCP Editors

Patients with heavily treated multiple myeloma showed rapid and durable responses to a novel treatment combination, according to a recent study published in Blood (July 2017;...

...

07/17/2017

Journal of Clinical Pathways

Research in Review

Immunotherapy Shows Promise in Rare Type of Lymphoma

07/11/2017

JCP Editors

A recent report demonstrates the promise of programmed death (PD-1) inhibition in improving outcomes for patients with a rare, difficult-to-treat type of lymphoma, published in The New England Journal of Medicine...

A...

07/11/2017

Journal of Clinical Pathways

Research in Review

CAR-T Therapy Response Independent of Disease Factors in NHL

07/10/2017

JCP Editors

A recent clinical trial of a chimeric antigen receptor (CAR) T-cell therapy showed a significantly high response rate in treatment-resistant and relapsed aggressive non-Hodgkin lymphoma (NHL) independent of disease...

A...

07/10/2017

Journal of Clinical Pathways

Research in Review

Novel Prognostic Biomarker Identified in DLBCL

06/23/2017

JCP Editors

A new prognostic indicator involving monocytes has been identified for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), according to research presented at the 22nd Congress of the European...

A new...

06/23/2017

Journal of Clinical Pathways

Research in Review

Higher Dose Does Not Improve Efficacy of Gastric Cancer Treatment

06/20/2017

JCP Editors

A higher dose treatment for a type of metastatic gastric adenocarcinoma showed equivalent efficacy and safety, according to research published in the Journal of Clinical Oncology (published online June 2017;...

A...

06/20/2017

Journal of Clinical Pathways

Research in Review

Earlier Endpoint May Be Predictive of Lung Cancer Therapy Outcomes

06/16/2017

JCP Editors

A novel intermediate endpoint could be a useful measure in clinical trials for metastatic non-small cell lung cancer (mNSCLC), according to a recent study published in JAMA (published online June 15, 2017;...

A...

06/16/2017

Journal of Clinical Pathways